特别关注｜PD-1/PD-L1在肝细胞癌治疗中的应用(12)

孙永琨. 2018《CSCO原发性肝癌诊疗指南》解读——全身治疗部分[J/CD]. 肝癌电子杂志, 2018, 5(3): 11-14.
[10]National Comprehensive Cancer Network(NCCN). Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers, Version 1.2020.[EB/OL]. (2020-03-23)[2020-06-20]. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf.
[11]ZHU AX, FINN RS, EDELINE J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952. DOI: 10.1016/S1470-2045(18)30351-6
[12]KUDO M, FINN RS, EDELINE J, et al. Updated efficacy and safety of KEYNOTE-224: A phase Ⅱ study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC)[J]. J Clin Oncol, 2020, 38(4 Suppl): 518.
[13]FINN RS, RYOO BY, MERLE P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase Ⅲ trial[J]. J Clin Oncol, 2020, 38(3): 193-202. DOI: 10.1200/JCO.19.01307